Improved survival with vemurafenib in melanoma with BRAF V600E mutation PB Chapman, A Hauschild, C Robert, JB Haanen, P Ascierto, J Larkin, ... New England Journal of Medicine 364 (26), 2507-2516, 2011 | 9220 | 2011 |
Inhibition of mutated, activated BRAF in metastatic melanoma KT Flaherty, I Puzanov, KB Kim, A Ribas, GA McArthur, JA Sosman, ... New England Journal of Medicine 363 (9), 809-819, 2010 | 4309 | 2010 |
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET H Peinado, M Alečković, S Lavotshkin, I Matei, B Costa-Silva, ... Nature medicine 18 (6), 883-891, 2012 | 3968 | 2012 |
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial A Hauschild, JJ Grob, LV Demidov, T Jouary, R Gutzmer, M Millward, ... The Lancet 380 (9839), 358-365, 2012 | 3553 | 2012 |
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma G Bollag, P Hirth, J Tsai, J Zhang, PN Ibrahim, H Cho, W Spevak, C Zhang, ... Nature 467 (7315), 596-599, 2010 | 2066 | 2010 |
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion R Straussman, T Morikawa, K Shee, M Barzily-Rokni, ZR Qian, J Du, ... Nature 487 (7408), 500-504, 2012 | 1984 | 2012 |
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E) PI Poulikakos, Y Persaud, M Janakiraman, X Kong, C Ng, G Moriceau, ... Nature 480 (7377), 387-390, 2011 | 1666 | 2011 |
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study GA McArthur, PB Chapman, C Robert, J Larkin, JB Haanen, R Dummer, ... The lancet oncology 15 (3), 323-332, 2014 | 1216 | 2014 |
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors F Su, A Viros, C Milagre, K Trunzer, G Bollag, O Spleiss, JS Reis-Filho, ... New England Journal of Medicine 366 (3), 207-215, 2012 | 1208 | 2012 |
Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at … TZ Horvat, NG Adel, TO Dang, P Momtaz, MA Postow, MK Callahan, ... Journal of Clinical Oncology 33 (28), 3193-3198, 2015 | 1105 | 2015 |
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial GV Long, U Trefzer, MA Davies, RF Kefford, PA Ascierto, PB Chapman, ... The lancet oncology 13 (11), 1087-1095, 2012 | 1029 | 2012 |
KIT as a therapeutic target in metastatic melanoma RD Carvajal, CR Antonescu, JD Wolchok, PB Chapman, RA Roman, ... Jama 305 (22), 2327-2334, 2011 | 1026 | 2011 |
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma PB Chapman, LH Einhorn, ML Meyers, S Saxman, AN Destro, ... Journal of Clinical Oncology 17 (9), 2745-2745, 1999 | 998 | 1999 |
Evolutionary dynamics of cancer in response to targeted combination therapy I Bozic, JG Reiter, B Allen, T Antal, K Chatterjee, P Shah, YS Moon, ... elife 2, e00747, 2013 | 695 | 2013 |
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort … JL McQuade, CR Daniel, KR Hess, C Mak, DY Wang, RR Rai, JJ Park, ... The Lancet Oncology 19 (3), 310-322, 2018 | 568 | 2018 |
The advantages of targeted protein degradation over inhibition: an RTK case study GM Burslem, BE Smith, AC Lai, S Jaime-Figueroa, DC McQuaid, ... Cell chemical biology 25 (1), 67-77. e3, 2018 | 568 | 2018 |
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner EW Joseph, CA Pratilas, PI Poulikakos, M Tadi, W Wang, BS Taylor, ... Proceedings of the National Academy of Sciences 107 (33), 14903-14908, 2010 | 513 | 2010 |
Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival GY Ku, J Yuan, DB Page, SEA Schroeder, KS Panageas, RD Carvajal, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2010 | 497 | 2010 |
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial RD Carvajal, JA Sosman, JF Quevedo, MM Milhem, AM Joshua, ... Jama 311 (23), 2397-2405, 2014 | 468 | 2014 |
Variates of survival in metastatic uveal melanoma P Rietschel, KS Panageas, C Hanlon, A Patel, DH Abramson, ... Journal of Clinical Oncology 23 (31), 8076-8080, 2005 | 372 | 2005 |